PATRICIA MEZZINA: Open Payments
NPI 1275126591 · NEPTUNE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,158 in 40 payments from 11 companies in 2025. Trend: 2023 $1,973 · 2024 $1,153 · 2025 $1,158
Food & beverage: $1,158
| Company | Payments | Amount |
|---|---|---|
| TG Therapeutics, Inc. | 11 | $327 |
| EMD Serono, Inc. | 4 | $239 |
| Novartis Pharmaceuticals Corporation | 5 | $125 |
| Amgen Inc. | 1 | $102 |
| Biogen, Inc. | 4 | $98 |
| Genentech USA, Inc. | 5 | $94 |
| GENZYME CORPORATION | 3 | $56 |
| Alexion Pharmaceuticals, Inc. | 3 | $48 |
| Celgene Corporation | 2 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
Products named: BRIUMVI, KESIMPTA, UPLIZNA, Mavenclad, TYSABRI, Ocrevus Zunovo, ULTOMIRIS, ZEPOSIA.
Industry payments across NJ — which companies pay providers there.
